AI filing briefs · archive

8-K filings in July 2026, explained

1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 1,916 briefs match

newest first · times in ET

NPCENeuroPace Inc Jul 28, 4:31 PM ET

NeuroPace says FDA deems IGE indication filing not approvable in its current form

Negative legal/regulatory Written later 7.01

NeuroPace received an FDA communication that its Premarket Approval Supplement to expand the RNS System indication to drug-resistant idiopathic generalized epilepsy is not approvable as submitted, and FDA has requested additional clinical evidence. The company says it will file a Submission Issue Request and amend the submission, and that its guidance does not include any contribution from the expanded indication.

FDA communication was received on the PMA-S target due date, and the company says it has begun working with FDA on the review team and a subsequent SIR meeting.
FDA requested additional clinical evidence from the NAUTILUS trial and literature supporting the submission.
At 18 months, patients treated with the RNS System had a 77% median reduction in GTC seizures from baseline, and 40% achieved GTC seizure freedom.
Full second quarter 2026 results and any full year outlook updates are scheduled for the August 11, 2026 earnings call.

Read the filing on SEC.gov ↗

GRCEGrace Therapeutics, Inc. Jul 28, 7:16 AM ET

Grace Therapeutics receives FDA Type A meeting minutes on GTx-104 resubmission path

Neutral legal/regulatory Written later 8.01

Grace Therapeutics announced it received the FDA's official minutes from a Type A meeting on the April 23, 2026 Complete Response Letter for GTx-104. The company says the FDA cited facility-level cGMP issues at its contract manufacturer and additional leachables and excipient data, and it is adding a second, U.S.-based contract manufacturer as a backup route to resubmission. The filing gives no resubmission date, so the timing of a possible approval remains open.

FDA Type A meeting minutes received; CRL issued April 23, 2026 for GTx-104 new drug application
FDA did not identify clinical safety or efficacy deficiencies and did not request additional clinical data
Company is pursuing a dual-source manufacturing strategy with a second U.S.-based contract manufacturer; no single resubmission path has been designated
Corporate presentation updated July 28, 2026 to reflect the path to NDA resubmission

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.